| Literature DB >> 30906553 |
Dawit Admassu1, Gudina Egata2, Zelalem Teklemariam3.
Abstract
OBJECTIVE: The aim of this study was to determine the prevalence and antimicrobial susceptibility pattern of Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi among febrile patients at Karamara Hospital, Jigjiga, eastern Ethiopia.Entities:
Keywords: Jigjiga; Karamara Hospital; Salmonella enterica serovar Paratyphi; Salmonella enterica serovar Typhi; drug susceptibility
Year: 2019 PMID: 30906553 PMCID: PMC6421600 DOI: 10.1177/2050312119837854
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Characteristics study participants who were presumptive of enteric fever at Karamara general Hospital, Jigjiga, eastern Ethiopia, 2016.
| Variables | Frequency (%) |
|---|---|
| Age in years | |
| 5–15 | 41 (20.5) |
| 16–30 | 79 (39.5) |
| 31–45 | 41 (20.5) |
| 46–60 | 19 (9.5) |
| ⩾60 | 20 (10) |
| Residence | |
| Urban | 145 (72.5) |
| Rural | 55 (27.5) |
| Educational status | |
| Not able to read and write | 125 (62.5) |
| Literate | 75 (37.5) |
| Source of water supply | |
| Pipe | 168 (84) |
| River/well | 32 (16) |
| Previous history of enteric fever infection | |
| Yes | 71 (35.5) |
| No | 129 (64.5) |
| Previous history of antimicrobial usage | |
| Yes | 176 (88) |
| No | 24 (12) |
Factors associated with prevalence of enteric fever (Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi) among presumptive enteric fever patients at Karamara general Hospital, Jigjiga, eastern Ethiopia, 2016.
| Variables | No. of patients examined (% Positive enteric fever) | Crude odds ratio (95% CI) | Adjusted odds ratio (95% CI) |
|---|---|---|---|
| Age in years | |||
| 5–15 | 41 (4.9) | 0.97 (0.08–11.43) | 3.28 (0.20–53.70) |
| 16–30 | 79 (11.4) | 2.44 (0.29–20.50) | 4.10 (0.47–35.57) |
| 31–45 | 41 (19.5) | 4.60 (.53–39.72) | 10.0 (1.07–93.12)[ |
| 46–60 | 19 (10.5) | 2.24 (0.19–26.91) | 2.60 (0.21–31.91) |
| >60 | 20 (5.0) | 1 | 1 |
| Previous history of antimicrobial usage | |||
| Yes | 176 (11.9) | 3.12 (0.004–24.29) | 1.21 (0.09–16.05) |
| No | 24 (4.5) | 1 | 1 |
| Previous history of enteric fever | |||
| Yes | 71 (19.7) | 3.72 (1.48–9.360) | 4.83 (1.73–13.49)[ |
| No | 129 (6.2) | 1 | 1 |
p ⩽ 0.05; **p ⩽ 0.01.
Antimicrobial susceptibility pattern of Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi isolated from presumptive enteric fever patients at Karamara general Hospital, Jigjiga, eastern Ethiopia, 2016.
| Antimicrobe | Susceptibility pattern | |||||
|---|---|---|---|---|---|---|
| Sensitive number (%) | Intermediate number (%) | Resistant number (%) | Sensitive number (%) | Intermediate number (%) | Resistant number (%) | |
| Ciprofloxacin | 5 (35.7) | 7 (50) | 2 (14.3) | 5 (62.5) | 1 (12.5) | 2 (25) |
| Nalidixic acid | 5 (35.7) | 6 (42.9) | 3 (21.4) | 2 (25) | 2 (25) | 4 (50) |
| Norfloxacin | 7 (50) | 4 (28.6) | 3 (21.4) | 3 (37.5) | 2 (25) | 3 (37.5) |
| Ampicillin | – | – | 14 (100) | – | – | 8 (100) |
| Tetracycline | 11 (78.6) | 3 (21.4) | – | 8 (100) | – | – |
| Gentamycin | 9 (64.3) | 3 (21.4) | 2 (14.3) | 8 (100) | – | – |
| Amoxicillin | – | – | 14 (100) | – | 2 (25) | 6 (75) |
| Ceftriaxone | 9 (64.3) | 4 (28.6) | 1 (7.1) | 4 (50) | 2 (25) | 2 (25) |
| Chloramphenicol | – | – | 14 (100) | – | – | 8 (100) |
Multiple drug resistances pattern of Salmonella enterica serovar Typhi and Salmonella enterica serovar Paratyphi isolated from presumptive enteric fever patients at Karamara general Hospital, Jigjiga, eastern Ethiopia, 2016.
| Salmonella species | Antimicrobials | Number of resistance isolates | Percentage (%) |
|---|---|---|---|
| Nal, Cip, Amp, Amc, C | 2 | 14.28 | |
| Nal, Nor, Amp, Amc, C | 1 | 7.14 | |
| Nor, Amp, Amc, C | 2 | 14.28 | |
| Gen, Amp, Amc, C | 2 | 14.28 | |
| Cef, Amp, Amc, C | 1 | 7.14 | |
| Amp, Amc, C | 6 | 42.86 | |
| Cip, Nal, Amc, Amp, C | 2 | 25 | |
| Nal, Nor, Amp, Amc, Cef | 2 | 25 | |
| Nor, Amp, Amc, C | 1 | 12.5 | |
| Amp, Amc, C | 2 | 25 | |
| Amp, C | 1 | 12.5 |
Amp: ampicillin; Amc: amoxicillin; Nor: norfloxacin; Nal: nalidixic acid; Cip: ciprofloxacin; C: chloramphenicol; Gen: gentamycin; Cef: ceftriaxone.